Abstract
After three decades from the development of the hybridoma technology, a monoclonal antibody-based therapy targeting the inflammatory cytokine has been established as an ultimate treatment for chronic inflammatory diseases. Interleukine-6 (IL-6) is one of the inflammatory cytokines playing a pivotal role in these conditions, and strategies targeting IL-6 signal show promise in the treatment of chronic inflammatory diseases such as rheumatoid arthritis, juvenile idiopathic arthritis, and Crohns disease. Although many groups have been exploring the approach to block the IL-6 signal, tocilizumab, a humanized monoclonal antibody of the IL-6 receptor, has been the most intensively studied agent for clinical use. Clinical trials regarding chronic inflammatory diseases described above have demonstrated efficacy of tocilizumab, however, this treatment has limitations in terms of economic costs and ease of administration, and further advances are necessary to expand the concept of IL-6-specific therapeutics. In this review, we discuss targeting IL-6 in a rational drug design and present the various strategies to achieve this.
Keywords: Interleukin-6 (IL-6), IL-6 receptor, tocilizumab, adenovirus, rheumatoid arthritis, Castleman's disease
Current Pharmaceutical Design
Title: The Blockade of IL-6 Signaling in Rational Drug Design
Volume: 14 Issue: 12
Author(s): Yasuo Adachi, Naoko Yoshio-Hoshino and Norihiro Nishimoto
Affiliation:
Keywords: Interleukin-6 (IL-6), IL-6 receptor, tocilizumab, adenovirus, rheumatoid arthritis, Castleman's disease
Abstract: After three decades from the development of the hybridoma technology, a monoclonal antibody-based therapy targeting the inflammatory cytokine has been established as an ultimate treatment for chronic inflammatory diseases. Interleukine-6 (IL-6) is one of the inflammatory cytokines playing a pivotal role in these conditions, and strategies targeting IL-6 signal show promise in the treatment of chronic inflammatory diseases such as rheumatoid arthritis, juvenile idiopathic arthritis, and Crohns disease. Although many groups have been exploring the approach to block the IL-6 signal, tocilizumab, a humanized monoclonal antibody of the IL-6 receptor, has been the most intensively studied agent for clinical use. Clinical trials regarding chronic inflammatory diseases described above have demonstrated efficacy of tocilizumab, however, this treatment has limitations in terms of economic costs and ease of administration, and further advances are necessary to expand the concept of IL-6-specific therapeutics. In this review, we discuss targeting IL-6 in a rational drug design and present the various strategies to achieve this.
Export Options
About this article
Cite this article as:
Adachi Yasuo, Yoshio-Hoshino Naoko and Nishimoto Norihiro, The Blockade of IL-6 Signaling in Rational Drug Design, Current Pharmaceutical Design 2008; 14 (12) . https://dx.doi.org/10.2174/138161208784246072
DOI https://dx.doi.org/10.2174/138161208784246072 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Osteopontin; as a Target Molecule for the Treatment of Inflammatory Diseases
Current Drug Targets Latest Updates in Dengue Fever Therapeutics: Natural, Marine and Synthetic Drugs
Current Medicinal Chemistry Lymphatic Endothelial Cells, Inflammatory Lymphangiogenesis, and Prospective Players
Current Medicinal Chemistry Regulation of Nociceptive Transmission at the Periphery Via TRPA1-TRPV1 Interactions
Current Pharmaceutical Biotechnology Clinical Experience with Specific COX-2 Inhibitors in Arthritis
Current Pharmaceutical Design Conjugates of Cell Adhesion Peptides for Therapeutics and Diagnostics Against Cancer and Autoimmune Diseases
Current Topics in Medicinal Chemistry Biologic Therapy in Immune Mediated Inflammatory Disease: Basic Science and Clinical Concepts
Current Drug Safety RAGE as a Receptor of HMGB1 (Amphoterin): Roles in Health and Disease
Current Molecular Medicine Mass Spectrometry Data Analysis in the Proteomics Era
Current Bioinformatics Successful Treatment for Severe Thyroid-associated Ophthalmopathy with Tocilizumab
Endocrine, Metabolic & Immune Disorders - Drug Targets Vitamin D Insufficiency and Diabetes Risks
Current Drug Targets Drug Repurposing: An Emerging Tool for Drug Reuse, Recycling and Discovery
Current Drug Research Reviews Antioxidative Properties of Flavonoids
Current Organic Chemistry Expression and Function of the Leukocyte Integrins in Medicine
Current Genomics Treatment of Large Vessel Vasculitis
Current Immunology Reviews (Discontinued) Targeting the Tumor Microenvironment by Intervention in Interleukin-1 Biology
Current Pharmaceutical Design Targeting JAK3 Tyrosine Kinase-Linked Signal Transduction Pathways with Rationally-Designed Inhibitors
Anti-Cancer Agents in Medicinal Chemistry High-density Lipoprotein, Vascular Risk, Cancer and Infection: A Case of Quantity and Quality?
Current Medicinal Chemistry Monocytes and Macrophages as Cellular Targets in Liver Fibrosis
Inflammation & Allergy - Drug Targets (Discontinued) Trafficking of HIV-1 RNA: Recent Progress Involving Host Cell RNABinding Proteins
Current Genomics